National Institute of Allergy and Infectious Diseases (NIAID) – NIAID has been a major supporter of SIGA antiviral countermeasure development, awarding approximately $35.8 million in funding since 2003. Office of Biodefense Research Affairs (OBRA) – In addition to administering the major contract supporting ST-246® development, OBRA has provided access to animal models and testing capabilities. Department of Defense (DOD) – Several federal appropriations administered by the U.S. Army and the U.S. Air Force have supported SIGA’s programs. The Defense Threat Reduction Agency (DTRA) – DTRA has provided essential funding to enable the testing of ST-246® in monkeypox and smallpox infected non-human primates under BSL-3 and BSL-4 conditions, respectively. The United States Army Medical Research Institute for Infectious Diseases (USAMRIID) – SIGA has numerous ongoing projects with scientists at USAMRIID to test viral countermeasures against smallpox, Ebola and Lassa fever. Defense Science and Technology Laboratories (DSTL) – At Porton Down in the U.K., SIGA is working with DSTL scientists to test the effectiveness of ST-246® in murine aerosol challenge models. Centers for Disease Control and Prevention (CDC) - All of the in vitro and in vivo testing of ST-246® against variola virus has been conducted at the CDC BSL-4 laboratories in Atlanta. In addition, SIGA worked closely with CDC scientists on the treatment of an extreme eczema vaccinatum case that was conducted under an eIND in 2007. (eIND is emergency Investigational New Drug application) Biomedical Advanced Research and Development Authority (BARDA) – BARDA acquires vaccines and drugs for Project BioShield as well as countermeasures for emerging infectious diseases.